ABSTRACT:
Objectives: COVID-19 (Coronavirus Disease 2019) infections have been related to a variety of fungal and bacterial co-infections. This case report includes the case of a COVID-19-infected patient who acquired rhino-orbital mucormycosis after undergoing COVID-19 treatment. We have discussed a COVID-19-infected patient who developed rhino-orbital mucormycosis during treatment in this case report8. Case Report: A 32-year-old female patient was admitted for treatment after testing positive for SARS-CoV-2 by reverse transcriptase polymerase chain reaction (RT-PCR). She was later diagnosed with rhino-orbital mucormycosis. She received dexamethasone i.v BD and on Oxygen over the course of the admission; she developed symptoms of orbital cellulitis after few days. Soft tissue edoema was found in the left eye and paranasal sinuses on magnetic resonance imaging (MRI). A nasal biopsy revealed broad aseptate filamentous fungal hyphae, which led to the diagnosis of mucormycosis. Conclusions: The use of steroids and oxygen therapy often may result in the development or worsening of a fungal infection. Doctors should be concerned about the possibility of secondary invasive fungal infections in patients who already have COVID-19 infection.